Pre-earnings options volume in Emergent BioSolutions is 2.0x normal with calls leading puts :. Implied volatility suggests the market is anticipating a move near 25.1%, or 82c, after results are released. Median move over the past eight quarters is 11.5%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EBS:
- Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
- Biotech Alert: Searches spiking for these stocks today
- Emergent Biosolutions Welcomes Joseph Papa as New CEO
- Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
- Emergent BioSolutions appoints Papa as new president, CEO